By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MabCure, Inc. 

3702 South Virginia Street
Suite G12-401
Reno  Nevada  89502  U.S.A.
Phone: 601-432-7447 Fax:



Company News
MabCure, Inc. Announces Agreement with the City University of New York Center for Advanced Technology to Validate and Evaluate its Monoclonal Antibodies as Ovarian Cancer Diagnostic Reagents 3/19/2012 8:10:17 AM
MabCure, Inc. Announces Completion of Its Ovarian Cancer Diagnostic Study in Thailand 12/16/2011 6:59:34 AM
MabCure, Inc. Receives U$500,000.00 Licensing Fee as Well as 12.5% Ongoing Royalty for Its Prostate Cancer Diagnostic Technology 11/23/2011 9:22:32 AM
MabCure, Inc. Study Results on a New Ovarian Cancer Diagnostic Blood Test Being Presented at the Annual Meeting of the Society of Gynecological Oncologists 3/8/2011 8:27:58 AM
MabCure, Inc., Corporate Update 3/1/2011 11:15:56 AM
MabCure, Inc. Secures $10 Million Funding Commitment from an Institutional Investor Managed by Roswell Capital Partners 1/20/2011 6:29:43 AM
MabCure, Inc. Welcomes Dr. Charles T. Tackney as New Chief Scientific Officer 12/6/2010 11:40:36 AM
MabCure, Inc. Completes 23.1 Million Australian Dollar Private Placement 12/6/2010 7:32:03 AM
MabCure, Inc. Generates Tumor Specific Antibodies against Prostate Cancer Which Could Lead to a Blood/Urine Diagnostic Test for Prostate Cancer 11/8/2010 12:07:54 PM
MabCure, Inc. Files Provisional Patent in the U.S. for Ovarian Cancer Antibodies 8/3/2010 9:29:27 AM